Publications
CAR T Cells
G-Rex®6 Well Plate
Publication Date: May 31, 2023
Allogeneic T cells engineered with a bicistronic CD20xCD22 dual CAR and TALEN-mediated TRAC and CD52 knockouts killed B-cell lymphoma targets that carried either antigen alone or both. Against Raji and JeKo-1 lines the dual CAR lysed cells dose-dependently and kept killing through repeated tumor challenges every three days for up to 11 days, while single CD22 CAR T cells lost control of CD20-positive, CD22-negative cells. In disseminated Daudi and subcutaneous Raji models, doses of 1, 3 and 10 million CAR-positive cells cleared tumor and extended survival, and the cells persisted in bone marrow beyond 100 days. Sixteen of 21 primary B-NHL samples were killed with IFN-gamma release, and a…
Publications
Other
G-Rex®6 Well Plate
Publication Date: May 16, 2023
T cells carrying the chimeric engulfment receptor CER-1236, which joins the phosphatidylserine-binding TIM-4 domain to TLR2/TIR, CD28 and CD3ζ signaling, both kill tumor cells and engulf them. In vitro, CER-1236 T cells eliminated 87% of PS-exposing JeKo-1 mantle cell lymphoma cells within 120 h, and over 60% took up PS-coated beads. BTK or EGFR inhibitors raised surface PS on tumor cells and strengthened killing. In NSG mice, CER-1236 cleared REC-1 lymphoma in 11/11 animals with ibrutinib and 9/9 without it. In an NSCLC xenograft, osimertinib plus CER-1236 produced the largest tumor regression. After engulfing antigen-bearing tumor cells, CER-1236 T cells also activated E7-specific TCR T…
Publications
T-Cells
G-Rex®10, G-Rex®100, G-Rex®100M
Publication Date: May 12, 2023
IMA101, an autologous multi-target T-cell therapy directed against up to four peptide-HLA cancer targets per patient, proved feasible and well tolerated in a first-in-human trial in advanced solid tumors. Of 214 patients screened, 43 completed leukapheresis, and 14 received T-cell products after fludarabine and cyclophosphamide lymphodepletion plus low-dose interleukin-2; some also received atezolizumab. Cytokine release syndrome was mild (grade 1 in six, grade 2 in four patients), with no neurotoxicity and no deaths in the first 100 days. No objective responses occurred, but three patients had disease stabilization lasting 7.3 to 13.7 months. Target-specific T cells reached up to 78.7% o…
Publications
CAR T Cells, Treg Cells
G-Rex®6 Well Plate
Publication Date: May 4, 2023
A chemically inducible IL-2 receptor signaling complex (CISC), built from FKBP–IL2RG and FRB–IL2RB fusion proteins, lets researchers select and expand gene-edited primary CD4+ T cells with rapamycin in place of IL-2. Placed at the FOXP3 locus, it enriched engineered Treg from under 20% edited cells to 40%–95% purity across five donors, and the cells showed Treg-like phenotype and suppressed effector T cells similarly to thymic Treg. In immunodeficient mice, rapamycin increased engraftment of CISC Treg without exogenous IL-2, and the dimerizer AP21967 improved GvHD outcomes at a subtherapeutic cell dose. A TRAC-targeted CD19-CAR version reached more than 70% CAR+ cells after 19 days of rap…
Publications
VST Cells
G-Rex®100
Publication Date: May 3, 2023
Rhesus macaque CD8-dominant T cells specific for HIV/SIV conserved elements can be expanded ex vivo from vaccinated animals, including SHIV-infected, ART-suppressed ones, and infused safely, though they did not persist or protect. Conserved-element DNA-vaccinated macaques donated 30-50 mL of blood; cells were stimulated with peptide-pulsed dendritic cells, then PHA blasts and irradiated GM-K562 feeders, and expanded in G-Rex® 100 flasks. Total viable cells rose a median 3-fold from day 0 to 11 and more than 5-fold from day 11 to 17, with no yield difference by SHIV status or ART. Products were nearly all CD8+ effector cells (median CD4:CD8 ratio 0.02). Two infused animals showed no differ…
Publications
NK Cells
Publication Date: May 2, 2023
Allogeneic natural killer (NK) cell therapy will need manufacturing processes that borrow from protein biologics production while treating the cells themselves as the final product. This review describes NK cell sources, including donor peripheral blood, cord blood, induced pluripotent stem cells and the NK-92 line, and the central role of engineered K562 feeder cells in expansion. Co-culture with K562/mbIL-21–4-1BBL feeder cells gave 10^4- to more than 10^6-fold expansion over 3–7 weeks. Current clinical-scale systems include bags, G-Rex® flasks and the CliniMACS Prodigy, whereas future scale may need 10–100 L stirred tanks, perfusion with cell retention, in-line sensing under process an…
Publications
B Cells
G-Rex®6 Well Plate
Publication Date: April 24, 2023
Human monoclonal antibodies isolated from the only known survivor of Sosuga virus infection neutralize the virus potently, and antibodies against the attachment protein HN were generally stronger than those against the fusion protein F. Memory B cells from a leukapheresis sample taken five years after infection yielded 24 antibodies, 6 against HN and 18 against F. The HN antibodies all bound the globular head and fell into four competition groups. The F antibodies split into prefusion-specific, postfusion-specific and dual-reactive classes with eight competition groups. All but the single postfusion-specific antibody neutralized authentic virus, and rSOSV-24 reached an IC50 of 0.4 ng/mL.
Publications
CAR T Cells
G-Rex®6M Well Plate
Publication Date: April 12, 2023
Lowering the affinity of an EpCAM-directed CAR spared primary human epithelial cells but weakened tumor control in vivo, and adding NFAT-driven inducible IL-12 to the same construct restored anti-tumor activity. Alanine scanning of CDR-H3 in the UBS54 scFv identified Tyr6 as the critical residue, and substituting valine gave a KD of 10.8 μM against 0.88 ± 0.19 μM for the parent. In subcutaneous SNU-638 gastric xenografts in NSG mice given 1 × 10^7 T cells, Y6V-iIL-12 suppressed growth significantly better than Y6V alone, leaving about 60% of mice below 300 mm³. With an ICAM-1 CAR, F292A-iIL-12 made all mice tumor-free, 1 of 16 relapsing, and serum IL-12 stayed far below 1 ng/ml.
Publications
Other
Publication Date: April 7, 2023
Manufacturing red blood cells in vitro is a promising answer to donor-dependent blood shortages, but output remains below what a transfusion needs. A single adult unit requires more than 2×10^12 cells, which would take about 1,000 L of medium in conventional 2D culture at 2×10^6 cells/mL. This review compares cell sources (primary stem cells, iPSCs, immortalized erythroblast lines) and 3D approaches, including bone-marrow-mimicking scaffolds, hollow-fiber, wave-type, roller-bottle, spinner-flask, stirred-tank and gas-permeable bioreactors. Reported scale-ups reached up to 3 L stirred-tank cultures, and a 1 L gas-permeable system gave 3×10^7-fold erythroblast expansion with over 90% enucle…
Publications
Other
Publication Date: April 5, 2023
Combining a rapid interferon-gamma secretion enrichment with a 12-day short-term expansion can generate Aspergillus fumigatus-specific T cells from the same donor blood for immediate and sustained treatment of invasive aspergillosis. Of 320 healthy donors screened, 65% had IFN-γ-secreting Aspergillus-specific T cells after lysate stimulation. Magnetic enrichment gave a mean 49.6% IFN-γ+ among CD3+ cells with Asp-lysate versus 35.3% with a peptide-pool mixture (PepMix). Twelve-day expansion met the release criterion of more than 80 spots per 10^5 cells in all donors tested, with mean responses of 863 (lysate) and 833 (PepMix) spots. Expanded cells were mainly Th1-polarized CD4+ memory cell…
Publications
CAR T Cells
Publication Date: March 31, 2023
This review summarizes how CAR T-cell therapy has been developed for relapsed or refractory mantle cell lymphoma (MCL), a B-cell malignancy that remains incurable. Brexucabtagene autoleucel (KTE-X19), a second-generation CD19-directed CAR T product, received USFDA approval on July 24, 2020 based on the ZUMA-2 trial. In ZUMA-2's efficacy cohort of 60 patients, the objective response rate was 93% with 67% complete responses; across all 74 treated patients it was 85% with 59% complete responses. Cytokine release syndrome occurred in 91% of patients, 15% at grade 3 or above. Limited tumor infiltration and limited trafficking remain barriers to successful CAR T-cell therapy.
Publications
CAR T Cells, T-Cells
G-Rex®10, G-Rex®100
Publication Date: March 30, 2023
Inhibiting the tyrosine phosphatases PTP1B and TCPTP boosts T cell activity and adoptive T cell therapy more effectively than degrading CDK6. Cyclin D3/CDK6 phosphorylates both phosphatases, raising their activity and lowering tyrosine phosphorylation of CD3 zeta, which dampens T cell activation. In mouse and human T cells, blocking this axis increased IFN-gamma and granzyme B production and memory differentiation. It also raised killing of tumor cells by OT-I and CD19 CAR T cells in vitro. In a melanoma pmel transfer model, 4 of 9 mice given the PTP inhibitor with T cells were tumor-free at 11 weeks, versus 1 of 9 with the CDK6 degrader and 0 of 5 with T cells alone. No toxicity was obse…
No manuscripts match your filters.